ABLi Therapeutics, Inc.
Biotechnology company developing brain-penetrant small-molecule inhibitors of Abl family (c-Abl) tyrosine kinases to treat Parkinson’s disease, multiple system atrophy, and other neurodegenerative disorders. Uses a data-driven re‑engineering approach to modify clinically validated kinase inhibitor chemotypes for improved brain penetration, potency, and safety and advances candidates through preclinical models and human clinical trials.
Industries
Nr. of Employees
small (1-50)
ABLi Therapeutics, Inc.
Atlanta, Georgia, United States, North America
Products
Oral small-molecule c-Abl kinase inhibitor (clinical candidate)
An orally administered, brain-penetrant small-molecule inhibitor of Abl-family tyrosine kinases developed to reduce pathogenic alpha-synuclein accumulation, restore Parkin function, and improve mitochondrial and neuronal health; advanced in Phase 1 and Phase 2 clinical trials.
Oral small-molecule c-Abl kinase inhibitor (clinical candidate)
An orally administered, brain-penetrant small-molecule inhibitor of Abl-family tyrosine kinases developed to reduce pathogenic alpha-synuclein accumulation, restore Parkin function, and improve mitochondrial and neuronal health; advanced in Phase 1 and Phase 2 clinical trials.
Services
Sponsor-driven clinical study design and execution for CNS indications including protocol development, multi-site operations, and biomarker incorporation.
Preclinical and mechanistic research partnerships investigating target engagement, disease biology, and biomarker strategies.
Sponsor-driven clinical study design and execution for CNS indications including protocol development, multi-site operations, and biomarker incorporation.
Preclinical and mechanistic research partnerships investigating target engagement, disease biology, and biomarker strategies.
Expertise Areas
- Neurodegenerative disease drug discovery
- Kinase inhibitor medicinal chemistry
- Preclinical in vivo pharmacology for synucleinopathies
- Clinical trial design and execution (Phases 1–3)
Key Technologies
- Small-molecule kinase inhibition
- Brain-penetrant CNS drug design
- In vivo rodent and nonhuman primate disease models
- Fluid and tissue biomarker assays
News & Updates
Company announced details of an End of Phase 2 meeting with the U.S. FDA to evaluate the clinical candidate for Parkinson’s disease.
Public announcement of company formation and strategic focus on developing treatments for neurodegenerative diseases arising from Abl kinase activation.
Press release reporting final results from the Phase 2 201 trial evaluating the clinical candidate in Parkinson’s disease.
Peer-reviewed clinical study report describing safety, tolerability, and pharmacokinetics of the clinical candidate in elderly volunteers and Parkinson’s patients.
Publication reporting that an Abl-family kinase inhibitor suppresses neurodegeneration in mouse models of hereditary and sporadic Parkinson’s disease.
Article discussing opportunities to modify Parkinson’s disease via Abl kinase inhibition.
Company announced details of an End of Phase 2 meeting with the U.S. FDA to evaluate the clinical candidate for Parkinson’s disease.
Public announcement of company formation and strategic focus on developing treatments for neurodegenerative diseases arising from Abl kinase activation.
Press release reporting final results from the Phase 2 201 trial evaluating the clinical candidate in Parkinson’s disease.
Peer-reviewed clinical study report describing safety, tolerability, and pharmacokinetics of the clinical candidate in elderly volunteers and Parkinson’s patients.
Publication reporting that an Abl-family kinase inhibitor suppresses neurodegeneration in mouse models of hereditary and sporadic Parkinson’s disease.
Article discussing opportunities to modify Parkinson’s disease via Abl kinase inhibition.